Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
Objective: To analyse at our institution the criteria for selecting a first-line therapy for patients with advanced radioiodine-refractory thyroid cancer and their clinical responses, safety and survival outcomes. Patients and methods: We extracted data from 69 consecutive patients referred to Feder...
Saved in:
Main Authors: | Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2025-02-01
|
Series: | European Thyroid Journal |
Subjects: | |
Online Access: | https://etj.bioscientifica.com/view/journals/etj/14/1/ETJ-24-0332.xml |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01) -
Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01) -
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01) -
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01) -
Development of animal models to study aggressive thyroid cancers
by: Shovan Dutta, et al.
Published: (2025-02-01)